October 18, 2016
The UK's National Institute for Health and Care Excellence (NICE) plans to fast-track recommendations for the most cost-effective new drugs. Treatments offering exceptional value for money could be cleared for NHS use up to three months earlier than at present under the new process. This 'lighter touch' scheme would be reserved for new drugs that are likely to be particularly cost-effective, ie a cost per quality-adjusted life year (QALY) of no more than £10,000 ($12,500). NICE is consulting on the planned changes until Jan. 13, 2017. The consultation document also proposes the introduction of a budget impact threshold of £20m per year to help manage the introduction of drugs that are cost-effective but have a very high price and so need special access arrangements.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.